Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : PYNG Technologies -- Ignore unavailable to you. Want to Upgrade?

To: the Chief who wrote (967)	3/16/1998 7:27:00 PM
From: Mr Metals	Read Replies (1) \| Respond to of 8117

They are in. Just remember U don't have to report your shorts. Someone is out to get PYNG/DD but it will not work in the long run. Don't these exchanges have anything better to do then to fuc# with a real company, that has a real product,that can make a big difference in our lives. MAY THE PYNG(THE FORCE)BE WITH YOU. Mr Metals

To: the Chief who wrote (967)	3/16/1998 8:24:00 PM
From: Kevin Garnier	Read Replies (1) \| Respond to of 8117

Chief, Tom and others -- please understand that my calculations are based on projections obtained from a fact sheet provided to me by an investor relations firm -- Frontline Marketing Group Inc. I received the overview in August of '97, so I guess the figures were relevant at the time. I did not include year 1 figures since that period has passed us by -- but for the record, earnings were listed as ($150,984) with EPS of ($0.02). Projections reflect sales in North America in year 1 and 2, with Europe and Asia beginning in year 3. I understand that projections do not reflect derivative product opportunities such as pediatric intraosseous infusion, and bone marrow aspiration. How long will it take to reach a share price of $30-$50? Who knows? It will move as the market dictates.. I'll stick with the 3 year period. That way I'll be pleasantly surprised if it reaches that range sooner. Anything can happen. Dare I say: "Remember the infamous BRE-X". From perusing material available to me, it appears that the primary target market for the F.A.S.T.1 is in pre-hospital emergency care (trauma and cardiac arrest). Therefore, I presume that the projections do not include sales to the military. I stand to be corrected on that. In any case potential sales to the military are comprised in two segments. First is the initial inventory and second the replenishment of inventory during times of military conflict. To attempt to arrive at a share price based on estimated sales five years hence is out of my league. Estimates and projections are based on assumptions which are believed to be reasonable. They involve significant elements of subjective judgement and analysis. Today's PR informing us that the FAST1 was successfully used on a conscious, live human subject is certainly great news. As indicated, this discovery means that market penetration will likely be greater and faster than is predicted in the company's financial projections. Stay focused people. We have a great little company here. Let the world beat a path to its door. Happy Investing! Kevin